Hepatitis C treatment and substance use disorders

Psychiatric Annals

Volumn 33, Issue 6, 2003, Pages 402-408

  Fireman, Marian ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; CANNABIS; CENTRAL STIMULANT AGENT; COCAINE; ILLICIT DRUG; INTERFERON; OPIATE; RIBAVIRIN;

ABSTINENCE; ALCOHOL CONSUMPTION; ANAMNESIS; BLOOD TRANSFUSION; BREAST FEEDING; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE TRANSMISSION; DRINKING BEHAVIOR; DRUG ABUSE; DRUG RESPONSE; GENOTYPE; HEALTH SERVICE; HEPATITIS C; HUMAN; INTRAVENOUS DRUG ABUSE; KIDNEY DISEASE; LIVER DISEASE; LIVER INJURY; LIVER TOXICITY; MORTALITY; MOTHER CHILD RELATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SMOKING; SUBSTANCE ABUSE; UNITED STATES; VIRUS REPLICATION; VIRUS TRANSMISSION;

EID: 0038819640     PISSN: 00485713     EISSN: None     Source Type: Journal    
DOI: 10.3928/0048-5713-20030601-10     Document Type: Review

References (31)

1. Seeff LB, Hoofnagle JH. Treatment of hepatitis C in the methadone patient. National Institutes of Health Consensus Development Conference: Comorbid conditions associated with hepatitis C. Hepatitis single topic conference: 2002. Hepatology. 2002;36(5 Suppl 1):103-7.
2. Schiff ER. Hepatitis C and alcohol. Hepatology. 1997;26(3 Suppl 1):39S-42S.
3. Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA. 2000;284:450-6.
4. Schiff ER. The alcoholic patient with hepatitis C virus infection. Am J Med. 1999;107(6B):95S-9S.
5. Lieber CS. Alcohol and hepatitis C. Alcohol Research and Health. 2001;25:245-54.
6. Regev A, Jeffers LJ. Hepatitis C and alcohol. Alcohol Clin Exp Res. 1999;23:1543-51
7. Peters MG, Terrault NA. Alcohol use and hepatitis C. Hepatology. 2002(5 Suppl 1);36:S220-5.
8. Wiley TE, McCarthy M, Breidi L, McCarthy M, Layden TJ. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology. 1998;28:805-9.
9. Pessione F, Degos F, Marcellin P, et al. Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. Hepatology. 1998;27:1717-22.
10. Tanaka T, Yabusako T, Yamashita T, et al. Contribution of hepatitis C virus to the progression of alcoholic liver disease. Alcohol Clin Exp Res. 2000;24(4 Suppl):112S-6S.
11. Ostapowicz G, Watson KJ, Locarnini S, Desmond PV. Role of alcohol in the progression of liver disease caused by hepatitis C virus infection. Hepatology. 1998;27:1730-5.
12. Loguercio C, Di Pierro M, Marino MP, et al. Drinking habits of subjects with hepatitis C virus-related chronic liver disease: prevalence and effect on clinical, virological, and pathological aspects. Alcohol and Alcoholism. 2000;35:296-301.
13. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997;349:825-32.
14. Oshita M, Hayashi N, Kasahara A, et al. Increased serum hepatitis C virus RNA levels among alcoholic patients with chronic hepatitis C. Hepatology. 1994;20:1115-20.
15. Cromie SL, Jenkins PJ, Bowden DS, Dudley FJ. Chronic hepatitis C: effect of alcohol on hepatic activity and viral titre. J Hepatol. 1996;25:821-6.
16. Bellentani S, Pozzato G, Saccoccio G, et al. Clinical course and risk factors of hepatitis C related liver disease in the general population: report from the Dionysos study. Gut. 1999;44:874-80.
17. Noda K, Yoshihara H, Suzuki K, et al. Progression of type C chronic hepatitis to liver cirrhosis and hepatocellular carcinoma - its relationship to alcohol drinking and the age of transfusion. Alcohol Clin Exp Res. 1996;20:95A-100A.
18. Ono K, Sata M, Murashima S, Fukuizumi K, Suzuki H, Tanikawa K. Biological responses to administered interferon in alcoholics. Alcohol Clin Exp Res. 1996;20:1560-3.
19. Okazaki T, Yoshihara H, Suzuki K, et al. Efficacy of interferon therapy in patients with chronic hepatitis C. Comparison between non-drinkers and drinkers. Scand J Gastroenterol. 1994;29:1039-43.
20. Ohnishi K, Matsuo S, Matsutani K, et al. Interferon therapy for chronic hepatitis C in habitual drinkers: comparison with chronic hepatitis C in infrequent drinkers. Am J Gastroenterol. 1996;91:1374-9.
21. Tabone M, Sidoli L, Laudi C, et al. Alcohol abstinence does not offset the strong negative effect of lifetime alcohol consumption on the outcome of interferon therapy. J Viral Hepat. 2002;9:288-94.
22. Zylberberg H, Fontaine H, Thepot V, Nalpas B, Brechot C, Pol S. Triggering of acute alcoholic hepatitis by alpha-interferon therapy. J Hepatol. 1999;30:722-5.
23. Edlin B. Prevention and treatment of hepatitis C in injection drug users. Hepatology. 2002;36(5 Suppl 1):S210-9.
24. Edlin BR, Seal KH, Lorvick J, et al. Is it justifiable to withhold treatment for hepatitis C from illicit drug users? N Engl J Med. 2001;345:211-5.
25. Davis GL, Rodrigue JR. Treatment of chronic hepatitis C in active drug users. N Engl J Med. 2001;345:215-7.
26. Stephenson J. Former addicts face barriers to treatment for HCV. JAMA. 2001;285:1003-5.
27. Sylvestre DL. Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug Alcohol Depend. 2002;67:117-23.
28. Backmund M, Meyer K, Von Zielonka M, Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology. 2001;34:188-93.
29. Sylvestre DL. Treatment of hepatitis C in the methadone patient. In: Co-morbid conditions associated with hepatitis C. Hepatitis Single Topic Conference, 26-28 April, 2002; Chicago, III. Alexandria, VA: American Association for the Study of Liver Diseases; 2002.
30. Hezode C, Lonjon I, Roudot-Thoraval F, et al. Impact of smoking on histological liver lesions in chronic hepatitis C. Gut. 2003;52:126-9.
31. Pessione F, Ramond M, Njapoum C, et al. Cigarette smoking and hepatic lesions in patients with chronic hepatitis C. Hepatology. 2001;34:121-5.